ALGS250321P2500
- 0.00
- 0.000.00%
Aligos Therapeutics Newsroom
Aligos Therapeutics Analyst Ratings
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $75
Aligos Therapeutics' Promising Clinical Advancements and Buy Rating Driven by Strong Market Potential
Aligos Therapeutics Analyst Ratings
H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $75
Piper Sandler Keeps Their Buy Rating on Aligos Therapeutics (ALGS)
H.C. Wainwright Initiates Aligos Therapeutics(ALGS.US) With Buy Rating, Announces Target Price $75
Analysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Aligos Therapeutics (ALGS)
Aligos Therapeutics Analyst Ratings
Aligos Therapeutics (ALGS) Receives a Buy From Piper Sandler
Piper Sandler Keeps Their Buy Rating on Aligos Therapeutics (ALGS)
Piper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)
Maintaining a Hold: Balancing Promise and Risk in Aligos Therapeutics' Clinical Pipeline
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and Aligos Therapeutics (ALGS)
Piper Sandler Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)
Analysts Offer Insights on Healthcare Companies: Agilent (A), Cytokinetics (CYTK) and Aligos Therapeutics (ALGS)
Aligos Therapeutics (ALGS) Gets a Buy From Piper Sandler
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), Aligos Therapeutics (ALGS) and Nektar Therapeutics (NKTR)
Piper Sandler Sticks to Its Buy Rating for Aligos Therapeutics (ALGS)
Aligos Therapeutics (ALGS) Receives a Buy From Piper Sandler